CompanyGraph
At a glance
- Depends onUpstream position: supplies 5 industries, depends on 1
- ScaleMarket cap is $1.46B, above the global median of $1.15B
- PositionOperating margin is 35.2%, higher than 95% of its Medical Instruments & Supplies peers (median 9.3%)
- Interpretations12 currently firing — 12
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.20%Above 5Y avg (0.91%)
Annual Rate
CNY 0.13Paid annual
Payout Ratio
53.7%Sustainable
Payback Period
83.3 yr
Last Ex-Dividend
May 20, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.80BCNY1.46B · vs all stocks (USD)
Trailing P/E
22.08xvs Medical Instruments & Supplies peers
Revenue (TTM)
1.84BCNY273.63M · vs all stocks (USD)
Profit Margin
25.26%vs Medical Instruments & Supplies peers
Beta
0.5410xvs all stocks
52-Week Change
-42.61%vs all stocks
Market Capitalization
9.80BCNY1.46B · vs all stocks (USD)
Enterprise Value
8.59BCNY1.28B · vs all stocks (USD)
Trailing P/E
22.08xvs Medical Instruments & Supplies peers
Forward P/E
19.98xvs Medical Instruments & Supplies peers
PEG Ratio
-2.60xvs Medical Instruments & Supplies peers
Price to Sales (TTM)
5.58xvs Medical Instruments & Supplies peers
Price to Book (MRQ)
2.03xvs Medical Instruments & Supplies peers
Enterprise to Revenue
4.66xvs Medical Instruments & Supplies peers
Enterprise to EBITDA
12.97xvs Medical Instruments & Supplies peers
Gross Margin
71.61%vs Medical Instruments & Supplies peers
Profit Margin
25.26%vs Medical Instruments & Supplies peers
Operating Margin
35.21%vs Medical Instruments & Supplies peers
Return on Assets (TTM)
5.93%vs Medical Instruments & Supplies peers
Return on Equity (TTM)
9.83%vs Medical Instruments & Supplies peers
Revenue (TTM)
1.84BCNY273.63M · vs all stocks (USD)
Revenue per Share (TTM)
2.06CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-3.90%vs Medical Instruments & Supplies peers
Gross Profit (TTM)
1.31BCNY194.49M · vs all stocks (USD)
EBITDA (TTM)
887.44MCNY131.80M · vs all stocks (USD)
Net Income (TTM)
465.44MCNY69.13M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-8.80%vs Medical Instruments & Supplies peers
Operating Cash Flow (TTM)
681.26MCNY101.18M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
708.59MCNY105.24M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1320CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.20%vs all stocks
5-Year Average Dividend Yield
0.91%vs all stocks
Payout Ratio
53.66%vs Medical Instruments & Supplies peers
Minority Interest (Equity)
497.12MCNYFY2025 · Dec 31, 2025Revenue
1.86BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
512.64MCNYFY2025 · Dec 31, 2025Gross Profit
1.35BCNYFY2025 · Dec 31, 2025Operating Income
654.41MCNY97.19M · vs all stocks (USD)
Pre-tax Income
643.11MCNYFY2025 · Dec 31, 2025Income Tax Expense
99.17MCNYFY2025 · Dec 31, 2025Net Income
543.95MCNYFY2025 · Dec 31, 2025EBIT
656.84MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
887.44MCNYFY2025 · Dec 31, 2025Research & Development
43.87MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
185.11MCNYFY2025 · Dec 31, 2025Other Operating Expenses
19.54MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.64MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
13.73MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5370CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5370CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
892.97MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
892.97MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
543.95MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-64.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
577.77MCNYFY2025 · Dec 31, 2025Free Cash Flow
460.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
843.54MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
543.95MCNYFY2025 · Dec 31, 2025Other Non-cash Items
39.69MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
8.26MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.13MCNYFY2025 · Dec 31, 2025Capital Expenditures
-116.89MCNYFY2025 · Dec 31, 2025Net Acquisitions
-158.66MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.59BCNYFY2025 · Dec 31, 2025Sale of Investments
5.87BCNYFY2025 · Dec 31, 2025Other Investing Activity
7.75MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
13.24MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
16.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-14.04MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-254.77MCNYFY2025 · Dec 31, 2025Other Financing Charges
-326.51MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-579.32MCNYFY2025 · Dec 31, 2025Shares Outstanding
895.29MSharesUpdated Aug 19, 2026Float Shares
467.13MSharesUpdated Aug 19, 2026% Held by Insiders
48.42%vs all stocks
% Held by Institutions
4.49%vs all stocks
Total Cash (MRQ)
2.38BCNY352.92M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.65CNYUpdated Aug 19, 2026Total Debt (MRQ)
220.20MCNY32.70M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0398xvs Medical Instruments & Supplies peers
Current Ratio (MRQ)
5.84xvs Medical Instruments & Supplies peers
Book Value per Share (MRQ)
5.65CNYUpdated Aug 19, 2026Total Assets
6.26BCNY929.91M · vs all stocks (USD)
Total Current Assets
3.80BCNYFY2025 · Dec 31, 2025Total Liabilities
852.12MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.47BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
193.72MCNYFY2025 · Dec 31, 2025Total Current Liabilities
658.40MCNYFY2025 · Dec 31, 2025Cash
840.67MCNYFY2025 · Dec 31, 2025Cash Equivalents
7.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
847.85MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.22BCNYFY2025 · Dec 31, 2025Accounts Receivable
265.72MCNYFY2025 · Dec 31, 2025Inventory
172.11MCNYFY2025 · Dec 31, 2025Accounts Payable
78.89MCNYFY2025 · Dec 31, 2025Short-term Debt
115.14MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.66MCNYFY2025 · Dec 31, 2025Long-term Debt
147.27MCNYFY2025 · Dec 31, 2025Common Stock (Book)
895.29MCNYFY2025 · Dec 31, 2025Retained Earnings
2.58BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.41BCNY803.35M · vs all stocks (USD)
Treasury Stock
41.57MCNYFY2025 · Dec 31, 202552-Week Low
10.19CNYUpdated Aug 19, 202652-Week High
19.64CNYUpdated Aug 19, 202652-Week Change
-42.61%vs all stocks
Beta
0.5410xvs all stocks
50-Day MA
11.10CNYUpdated Aug 19, 2026200-Day MA
14.03CNYUpdated Aug 19, 2026Avg 10-Day Volume
12.51MSharesUpdated Aug 19, 2026Avg 30-Day Volume
12.08MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.5200CNYUpdated Aug 19, 202612 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 35.2%, higher than 95% of its Medical Instruments & Supplies peers (median 9.3%)Significant
Operating margin: 0.35Industry median: 0.09Industry P95: 0.35Peers compared: 35.00
Financial Health
Altman Z-Score 8.72: safe zoneNotable
Altman Z-Score: 8.72
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $1.46B, above the global median of $1.15BNotable
Market cap (USD): 1,456,003,328.874Global Median: 1,146,734,693.424
Levered free cash flow is $105.24M, above the global median of $16.24MNotable
Levered free cash flow (USD): 105,240,464.051Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Lanxess AG
Tier 1ProductionThroughput-Bound ConversionFlowRule
Ardent Health Partners Inc.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
TriMas Corporation
Tier 1ProductionThroughput-Bound ConversionFlowRule
Terveystalo Oyj
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Wuxi Xinhongye Wire & Cable Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Shenzhen Lihexing Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
The Pennant Group, Inc.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Hunan Valin Wire & Cable Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Shenzhen Jufei Optoelectronics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Vijaya Diagnostic Centre Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Amoy Diagnostics Co., Ltd.
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And EquityMulti-Year FCF With Growth And Margin
Catalyst Pharmaceuticals Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin
NVIDIA Corporation
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And Margin